#United States #San Francisco #GI Partners #Charles River #Rose BioSolutions

GI Partners Completes Acquisition of CDMO and Cell Solutions Businesses

In a significant move for the biotechnology landscape, GI Partners, a prominent private investment firm, has announced the successful acquisition of the Contract Development and Manufacturing Organization (CDMO) and Cell Solutions businesses from Charles River Laboratories International, Inc. This acquisition marks the formation of Rose BioSolutions, a company now poised to lead in advanced therapy manufacturing, offering a cohesive suite of services tailored specifically for cell and gene therapy sectors.

Establishing Rose BioSolutions

On May 7, 2026, the announcement echoed through the sectors of biomedical research and manufacturing, as GI Partners articulated its commitment to establishing Rose Bio as an independent entity. The firm aims for Rose Bio to provide comprehensive solutions that encompass the entire process of advanced therapy manufacturing, from initial materials to final products.

Rose Bio will operate with an emphasis on flexibility and responsiveness, essential attributes in a rapidly evolving field characterized by stringent regulatory requirements and high-stakes innovation. The new entity seeks to address the increasing demands for cell and gene therapies, positioning itself uniquely by integrating all necessary services into a single, full-service model that can robustly support clients from inception to delivery.

Promoting Innovation and Efficiency

At the core of Rose Bio's strategy is its dedication to advancing therapy capabilities through innovation. By leveraging the combined experience and resources that GI Partners offers, Rose Bio plans to drive improvements in operational efficiencies while simultaneously reducing development timelines. This initiative is vital, as the demand for advanced therapies continues to accelerate.

Dave Kreter, Managing Director at GI Partners, underlined the vision behind Rose Bio's establishment: “Our aim was to create a dedicated company to serve the needs of cell and gene therapy development, capitalizing on strong operational histories from the acquired businesses.” He highlighted how the firm’s extensive experience in life sciences equips them to address the multifaceted challenges faced in this sector, promising enhanced growth prospects.

Commitment to Clients and Quality

Rose Bio is built upon the R.O.S.E. principles: Reliable, Outcome-driven, Scalable, and Excellent. These principles illustrate their commitment to delivering top-tier client service while adhering to rigorous industry standards, which is particularly critical when dealing with the complexities of biotherapeutics and cell therapies.

Ahmad Hussin, the newly appointed Global Head of CDMO and Chief Operating Officer at Rose Bio, emphasized the significance of having one trusted partner throughout the lifecycle of research and manufacturing. His confidence in the integrated portfolio offered by Rose Bio reflects the organization’s preparedness to meet increasing market demands, hence striving for reliability, quality, and scalability.

The establishment of Rose Bio allows GI Partners to ensure sustained investment in innovation while fostering a collaborative atmosphere with existing leadership teams. The partnership between GI Partners and Charles River Laboratories is set to continue, ensuring a smooth transition for all operational facets and facilitating a prosperous future for both parties.

Looking Forward

As Rose Bio looks to embed itself within the advanced therapy manufacturing sector, its operational hubs will be situated strategically across several key locations, including Rockville and Memphis in the USA, and Keele in the UK. Such a geographical spread is designed to maximize the reach and efficiency of their services, providing localized support to clients while maintaining a global perspective.

The journey that starts with this acquisition is just the beginning for Rose Bio. With a solid foundation and clear strategic vision, the company is set to make a notable impact on the cell and gene therapy landscape. The combination of GI Partners' financial backing and Rose Bio’s operational expertise is anticipated to yield significant advancements in therapeutic solutions, ultimately aimed at improving patient outcomes on a global scale.